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Abstract
Background: Untreated disorders of the adrenocortical 
system, such as Cushing’s or Addison’s disease, can be 
fatal, and accurate quantification of a patient’s cortisol 
levels is vital for diagnosis. The objective of this study 
was to assess the analytical performance of a new fully-
automated Elecsys® Cortisol II assay (second generation) 
to measure cortisol levels in serum and saliva.
Methods: Four European investigational sites assessed 
the intermediate precision and reproducibility of the 
Cortisol II assay (Roche Diagnostics) under routine con-
ditions. Method comparisons of the Cortisol II assay 
vs. liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), the gold standard for cortisol measurement, 
were performed. Cortisol reference ranges from three US 
sites were determined using samples from self-reported 
healthy individuals.
Results: The coefficients of variation (CVs) for repeatabil-
ity, intermediate precision, and reproducibility for serum 
samples were  ≤  2.6%,  ≤  5.8%, and  ≤  9.5%, respectively, 
and for saliva were  ≤  4.4% and  ≤  10.9%, and  ≤  11.4%, 
respectively. Agreement between the Cortisol II assay 
and LC-MS/MS in serum samples was close, with a slope 
of 1.02 and an intercept of 4.473 nmol/L. Reference range 
samples were collected from healthy individuals (n = 300) 
and serum morning cortisol concentrations (5–95th per-
centile) were 166.1–507 nmol/L and afternoon concentra-
tions were 73.8–291 nmol/L. Morning, afternoon, and mid-
night saliva concentrations (95th percentile) were 20.3, 
6.94, and 7.56 nmol/L, respectively.
Conclusions: The Cortisol II assay had good precision over 
the entire measuring range and had excellent agreement 
with LC-MS/MS. This test was found suitable for routine 
diagnostic application and will be valuable for the diag-
nosis of adrenocortical diseases.
Keywords: assay; cortisol; immunoassay; method com-
parison; performance evaluation.
Introduction
Diseases of the adreno-cortisol system – such as Cush-
ing’s disease and Addison’s disease – are rather rare 
conditions [1–3]; life-threatening on the one hand but 
treatable on the other [4]. Consequently, a straightforward 
diagnostic approach is of essential importance, and accu-
rate quantification of cortisol levels plays a key role in 
the diagnosis of patients with suspected disease [5]. Cor-
tisol levels are often measured from a patient’s serum or 
plasma, which reflects total cortisol, both free and bound. 
However, in patients with liver disease, those receiving 
estrogen treatment or with critical illness, total serum 
cortisol levels may be difficult to interpret because of the 
variation in binding proteins. Recently, quantification of 
cortisol in saliva has become more widely used since it is 
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considered of equal diagnostic relevance as serum but can 
be obtained more easily and non-invasively [6, 7]. Salivary 
cortisol is free (i.e. not bound) and is useful in patients 
with serum results that are challenging to interpret [8, 
9]. Very low salivary cortisol concentrations are typically 
found in healthy individuals (< 8 nmol/L at midnight) [10, 
11]. Therefore, accurate test results in the lower cortisol 
ranges are needed because this is where reproducibility 
is currently reduced but where diagnostic test decisions 
are often made.
Automated cortisol immunoassays are commercially 
available, which have acceptable precision and are widely 
used not only because of their high performance but also 
because of their speed, simplicity, and cost-effectiveness 
[12]. One major limitation of immunoassays is their specific-
ity with interference of structurally similar compounds, for 
example endogenous steroids such as cortisone, or other 
steroid drugs such as prednisolone or dexamethasone [13, 
14]. In addition, different immunoassays show high inter-
assay variation [12, 15].
Gas chromatography-tandem mass spectrometry 
(GC-MS/MS) is traditionally used as a reference method 
for serum cortisol quantification. The introduction of 
LC-MS/MS allowed the use of isotope dilution mass 
spectrometry also in routine testing; however, the appli-
cation of this technology is still very demanding and 
limited to very few laboratories at present [16–20] with 
The Reference Institute for Bioanalytics (RfB; Bonn, 
Germany) reporting only 2.7% (14/513) laboratories 
using LC-MS/MS in their last survey [21]. Consequently, 
immunoassays are still the mainstay of cortisol testing 
worldwide [22].
The first generation Elecsys® Cortisol assay (Roche 
Diagnostics) was introduced in April 2000 to measure cor-
tisol levels in serum, plasma, urine, and saliva and has 
been used for the quantification of cortisol in clinical lab-
oratories worldwide [23–26]. In order to improve the speci-
ficity of cortisol measurement, a novel second-generation 
cortisol assay (Elecsys® Cortisol II assay; Roche Diagnos-
tics) has been developed. Poly-clonal cortisol-specific 
antibodies in the first generation assay were switched to 
more specific monoclonal antibodies in the new assay. 
Both the first- and second-generation assays measure 
the total cortisol fraction in serum and the free cortisol in 
saliva [22, 23, 27]. Furthermore, the new test generation is 
traceable to a GC-MS/MS-based reference method accord-
ing to the concept of an unbroken chain of traceability 
in clinical laboratory testing. The objective of this study 
was to assess the analytical performance of the Cortisol II 
assay under field conditions in a multicenter performance 
evaluation study.
Materials and methods
Study sites and instruments
The technical evaluation of the Cortisol II assay was performed 
between June and November 2014 at four European investigational 
sites: three in Germany (Munich, Heidelberg, and Leipzig) and one in 
Belgium (Ghent). All sites used cobas e 411 analyzers for the Cortisol 
II assay experiments presented in this study. In addition to a cobas e 
411 system, the Leipzig site utilized a cobas e 601 analyzer.
Assay design
The Elecsys® Cortisol II assay is the second generation assay (Roche 
Diagnostics GmbH, Mannheim, Germany) and can be used to quan-
tify cortisol levels in serum, plasma (Li-heparin, K2-K3-EDTA), or 
saliva. Briefly, the sample is incubated with a biotinylated cortisol 
antibody along with a ruthenium complex labeled cortisol deriva-
tive to form an immune complex. Streptavidin-coated microparticles 
are added and the complex becomes bound to the solid phase via 
a biotin/streptavidin interaction. Once aspirated, the microparticles 
are magnetically captured onto the surface of an electrode within a 
measuring cell, a voltage is applied with an electrochemilumines-
cence signal as the readout. The sample volume required is 10 μL, 
the assay measuring range is 1.5–1750.0 nmol/L, and the entire pro-
cedure takes a total of 18 min [27]. The assay is calibrated using the 
Cortisol CalSet (Roche Diagnostics) and has been standardized to the 
Institute for Reference Materials and Measurements (IRMM; Geel, 
Belgium)/IFCC-451 panel (ID-GC/MS) for serum [28].
Ethics statement
The investigation and sample collection sites adhered to the Interna-
tional Conference on Harmonization guideline for Good Clinical Prac-
tice and conducted the study in accordance with the Declaration of 
Helsinki (revised version). The study was approved by the Local Eth-
ics Committees of the participating sites. All individuals participating 
in the reference range study signed an informed consent agreement.
Sample storage and handling
The control samples for the precision experiments were stored at 
– 80 °C at Roche Diagnostics GmbH before being shipped to the study 
sites. At the sites, the samples were stored at – 20 or – 80 °C. For the 
method comparison experiments, leftover, anonymized serum or 
plasma and saliva samples from daily routine were used. These were 
stored at – 20 °C until measurements, for a maximum of 12 weeks [29].
For the reference range assessments, serum or plasma was col-
lected using a 3.5-mL Vacutainer® Serum Separation Tube (SST). A 
serum sample was preferred, but alternatively, Li-heparin-plasma/
K2,-K3-EDTA plasma was used. Saliva was obtained using a cotton 
swab Salivette® device (Sarstedt, Germany). Samples were processed 
within 24 h of donation. For the samples obtained at midnight, these 
were stored at 2–8 °C and delivered to the collection sites in the morn-
ing hours, no later than 24 h after taken. After collection, all samples 
were stored at 2–8 °C for a maximum of 3 days then frozen at – 70 °C 
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Table 1: LC-MS/MS methods used for method comparison at the three study sites.
  Ghent   Leipzig   Munich
Instrument   LC Shimadzu
MS ABSciex Triple Quad 5500
  Serum: QTRAP® 6500
Saliva: QTRAP® 5500
  Water Acquity UPLC
Waters Xevo TQ-S
Ionization mode  APCI +   APCI +   ESI+
Mass transition   Cortisol: 363.2/121.1
Cortisol-d4: 367.2/121.1
  Cortisol: 363/121
Cortisol-d4: 367/121
  Cortisol 363/121
Cortisol-d3 366/121
Sample 
preparation
  Liquid/liquid extraction 
(serum and saliva)
  Protein precipitation
plus on-line SPE
Serum: 100 μL
Saliva: 50 μL
  Protein precipitation plus 
on-line SPE
Sample volume: 100 μL
Calibrators   In-house   Serum: MassChrom® Steroids 
(Chromsystems, Munich, Germany)
Saliva: in-house
  In-house
QC samples   NIST Reference material 971
UK NEQAS for Steroid 
Hormones
  Serum: MassChrom® Steroids 
(Chromsystems, Munich, Germany) and 
in-house pooled control
Saliva: in-house
  Serum pools (in-house)
PC Saliva 1 (Roche)
Generic QCs (in-house)
Intermediate 
precision
  8%   Serum: 2.9%–4.9%
Saliva: 4.5%–5.1%
  Serum pools: 1.3%–4.9%
PC Saliva 1: 3.6% Generic 
QCs: 5.8%–6.3%
Reference   Fiers et al. [32]
Janssens et al. [33]
  Serum: Ceglarek et al. [34], Gaudl et al. [35]
Saliva: Bae et al. [36]
  Suhr et al. [37]
Validation   CLSI C57 [38] and C62-A [39] 
guidelines
  According to the FDA guidance [40], EU 
guideline [41], and ICH guideline [42]
  Based on the EMA 
guideline [41]
ACPI, atmospheric pressure chemical ionization; ESI, electrospray ionization; NIST, National Institute of Standards and Technology; 
NEQAS, National External Quality Assessment Scheme; QC, quality control; SPE, solid phase extraction; TQ-S, tandem quadrupole mass 
spectrometer; UPLC, ultra performance liquid chromatography.
at the collection facilities. The handling of the saliva samples was in 
line with a previous study into the long-term stability of saliva corti-
sol [29]. At the end of the collection process, frozen specimens were 
shipped on dry ice to the Roche Diagnostics Indianapolis site in a 
thermally insulated container and were received at the destination 
in a frozen state. Good Laboratory Practices and national regulations 
for the shipping of samples were strictly followed. Upon receipt, the 
samples were stored at – 80 °C before being shipped to the study test-
ing site. The samples at the study testing sites were stored at – 70 °C 
until testing occurred. Samples that were not handled, stored, or 
shipped according to this procedure were excluded from the analysis.
Cross-reactivity
The cross-reactivity of the Cortisol II and Cortisol (generation 1) assays 
was determined using two human serum samples, one of which was 
spiked with potential cross-reactant compounds. The cortisol concen-
tration of the samples was approximately 165.5 nmol/L (60 μg/L) and 
551.7  nmol/L (200 μg/L) (conversion factor μg/L × 2.7586 = nmol/L). 
The spiked and non-spiked samples were tested in duplicate and 
the difference from the non-spiked sample represented the analyte 
concentration simulated by cross-reaction. The percentage of cross-
reaction was calculated using the following formula:
100  simulated cortisol concentrationCross-reactivity (%)
spiked cross-reactant concentration
×
=
The following cross-reactants were assessed: 
6-α-methylprednisolone (0.1 mg/L), cortisone (10 mg/L), dexametha-
sone (10 mg/L), prednisolone (0.1 mg/L), and prednisone (10 mg/L). 
The concentrations used to test the cross-reactivity were chosen 
based on those previously used to test the cross-reactivity of the first 
generation Cortisol assay [26]. These tests, in part, followed the Clini-
cal and Laboratory Standards Institute Evaluation Protocol (CLSI EP) 
07-A2 Guideline [30].
Precision and accuracy
Assay precision was evaluated using quality control samples which 
were provided by Roche Diagnostics. These were the serum con-
trol samples Preci Control Universal 1 and 2 (PC U1 and PC U2). In 
addition, five lots of human sample pools (HSP 01–05) spiked with 
cortisol were used: HSP 01 was a saliva control and HSP  02–05 were 
serum controls. The concentration of the control samples were deter-
mined by Roche and were defined as the target concentration. All 
precision experiments were performed in compliance with the CLSI 
EP 05-A3 guideline [31]. A minimum of 30 specimens (same matrix as 
the precision samples) were included in every run between the preci-
sion determinations to simulate normal laboratory conditions.
Repeatability (intra-assay) and intermediate (inter-assay) pre-
cision experiments were performed in a four-fold determination on 
the same day over 21 days. The resulting mean concentration and 
the coefficients of variation (CVs, %) were calculated. Reproducibil-
ity was evaluated at each site with five human sample pools (HSP 
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01–05), two QC materials (PCU 1 and 2) on a five-fold determination 
over 5 days. This resulted in 175 analyses per site, using three differ-
ent lots of reagent from all four sites.
The reference serum samples (HM 3/13A and HM 3/13B) from the 
RfB proficiency testing program were analyzed at each of the four Euro-
pean sites. The RfB runs a reference measurement procedure, which is 
done according to an International Organization for Standardization 
(ISO) standard by accredited laboratories only listed by the Joint Com-
mittee of Traceability in Laboratory Medicine (JCTLM), and is based on 
GC-MS. The assigned values for HM3/13A and HM3/13B were obtained 
by the RfB using this reference measurement  procedure. The samples 
were tested in a three-fold determination on three separate days.
Method comparison
Leftover, anonymized serum or plasma and saliva samples from daily 
routine were used for the method comparison experiments. The Cor-
tisol II assay was compared with the Cortisol assay (generation 1) on 
either the cobas e 411 or the cobas e 601 systems at the four study 
sites. The Cortisol II assay was also compared with in-house isotope 
dilution LC-MS/MS assays. The LC-MS/MS methods are summarized 
in Table 1. The general use of cortisol of LC-MS/MS in endocrine test-
ing has also been published elsewhere [17].
Reference range assessment
The reference range samples were collected from healthy individu-
als at three US sites between June and December 2014. The collec-
tion sites were Medical Research Center (Spartanburg, SC, USA), 
Premier Research (Austin, TX, USA), and Quest Research Institute 
(Bingham Farms, MI, USA). Testing was performed between October 
and December 2014 at the Washington University School of Medicine, 
Core Laboratory for Clinical Studies (St. Louis, MO, USA).
Key inclusion criteria were age  ≥  21 years, self-reported healthy 
status, no infectious disease or symptoms in the prior 8 weeks, and 
a minimum volume of 1 mL each of serum/plasma or saliva was 
required. Individuals were excluded if they were pregnant, lactat-
ing, using oral contraceptives,  receiving medication with corti-
sone/cortisol or hormone replacement therapy, or unable to read or 
understand and sign the informed consent/assent form.
In total, a minimum of 120 evaluable individuals were required 
to be recruited in order to calculate the 5th to 95th/2.5th to 97.5th 
(serum/plasma) and the 95th/97.5th (saliva) percentiles. For deter-
mination of the Cortisol II assay reference ranges, the population 
was required to have a distribution of race/ethnicities of 40% Afri-
can American/40% Caucasian/20% Hispanic, in a female to male 
ratio of approximately 1 : 1. Morning samples (n = 150 minimum 
required) were collected between 6 and 10 a.m. independent of 
waking time. Afternoon samples (n = 150 minimum required) were 
collected between 4 and 8 p.m. in order to have a closer view of 
circadian rhythm of cortisol, decreasing over the period a.m.-p.m.-
midnight. Midnight saliva samples were allowed to be collected at 
12 p.m. ± 30 min at a fixed time independent from the bedtime.
Data management and statistical analysis
The output from the Cortisol II assay was directly captured on the 
Windows-based computer-aided evaluation (WinCAEv), a Code of 
Federal Regulations (CFR) 21 Part 11 compliant electronic data cap-
ture software [43]. The WinCAEv software was run from a laptop 
attached to the cobas e 411 and cobas e 601 analyzers. Repeatability, 
intermediate precision, and reproducibility were calculated using 
the statistical programs SAS (version 9.3) and R (version 3.0.1, addi-
tive package VCA version 1.0.6), in compliance with the CLSI EP05-A3 
Guideline [31].
An outlier analysis was performed on the precision samples at 
the end of the study: the outliers results were defined according to 
the recommendations of the CLSI EP05-A3 guidelines [31]. Based on 
these, it was permitted to reject at most two results due to an outlier, 
which was equal to one part in a 21-day study. This was applied to 
each precision sample and each 21-day experiment. The recovery of 
the target value for each sample based on the median of all deter-
minations was calculated for accuracy experiments. Passing-Bablok 
regression analysis and Pearson correlation coefficients were used to 
assess the correlation of the method comparison studies in compli-
ance with CLSI EP09-A3 [44].
The reference range analysis was performed using SAS soft-
ware version 9.3 and R version 3.0.1. For serum and plasma samples, 
the 2.5th, 5th, 95th, and 95th percentiles were calculated. The 95th 
and 97th percentiles were reported for saliva samples. The limit of 
quantitation (LoQ) and the limit of detection (LoD) of the Cortisol II 
assay were calculated based on the CLSI EP17-A2 Guideline [45]. It is 
important that the LoD and LoQ were the same for both the serum/
plasma and saliva samples: for standardization of the assay, both 
serum/plasma and saliva samples were used to ensure no matrix 
effect. The LoD and LoQ results of the assay were not recorded as 
part of the study.
Results
Cross-reactivity
To assess the specificity of the new Cortisol II assay vs. 
the first generation one, compounds with similar struc-
tures to cortisol were measured on both assays. The new 
Cortisol II assay monoclonal antibody had an improved 
cross- reactivity profile compared with the Cortisol assay 
( generation 1) for 6-α-methylprednisolone, dexametha-
sone, and prednisolone (Table 2). Cross-reactivity levels 
were higher with the second generation assay vs. the first 
in the measurement of cortisone and prednisone, but both 
were still very low ( ≤  6.58%).
Precision and accuracy
Across the four European sites, the repeatability CVs for 
the HSP 01–05 samples (excluding outliers) ranged from 
0.8% to 4.4% (Table 3). For the PC U1 and PC U2 samples, 
the repeatability CVs were between 1.3% and 2.2%.
The intermediate precision CVs for the HSP 02–05 
serum samples ranged from 2.1% to 5.8%, but were 
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Table 2: Cross-reactivity of the first and second generation cortisol assay antibodies.
Substance   Concentration, mg/La  
 
Cortisol (generation 1) 
 
Cortisol II
Cross-reactivity, % Cross-reactivity, %
6-α-Methylprednisolone   0.1   389  12
Cortisone   10   0.30  6.58
Dexamethasone   10   0.08  ND
Prednisolone   0.1   171  7.98
Prednisone   10   0.28  2.23
aConcentration of substance added; ND, non-detectable.
Table 3: Precision results of the Cortisol II assay.
Sample Type n Target conc., 
nmol/La
Mean measured 
conc., nmol/Lb
Repeatability 
CV, %c
Intermediate 
precision CV, %c
Reproducibility 
CV, %
HSP 01 Saliva 414 8.43 8.44 2.8–4.4 5.0–10.9 11.4
HSP 02 Serum 416 96.0 99.7 1.1–2.2 2.3–4.2 6.8
HSP 03 Serum 418 489.0 482 0.8–2.3 2.1–4.8 7.5
HSP 04 Serum 418 982.0 966 1.1–2.5 2.7–5.6 9.5
HSP 05 Serum 336d 1605.0 1611 1.8–2.6 2.5–5.8 5.8
PC U1 Serum 418 304 310 1.4–2.2 1.9–4.1 4.6
PC U2 Serum 420 734 736 1.3–2.2 2.0–4.8 5.1
aThe target concentration was provided by the manufacturer; bmean concentration measured by the sites; crange of CVs observed across 
the four study sites; ddata from one site not included in this analysis due to samples initially being tested without dilution – retesting not 
 possible due to stability date being exceeded. Conversion of units: μg/dL × 27.59 = nmol/L; nmol/L × 0.0362 = μg/dL.
Table 4: Accuracy results of the Cortisol II assay.
RfB 
sample
  Sample 
type
  Target, 
nmol/L
  Accuracy 
per center 
range, %
  CV of accuracy 
results across all 
centers, %
HM 3/13A  Serum   667  – 8.3 to + 1.4  – 0.9
HM 3/13B  Serum   365  – 5.9 to + 0.1  – 0.7
higher for the saliva sample (HSP 01, 5.0%–10.9%). 
The intermediate precision CVs for the two PC control 
samples were between 1.9% and 4.8%. Reproducibility 
CVs across the four laboratories ranged from 5.8% to 
9.5% for the HSP 02–05 serum samples, and 11.4% for 
the saliva HSP 01 sample. The reproducibility CVs were 
4.6%–5.1% for the PC U1 and PC U2 control samples, 
respectively.
A test of the accuracy of the assay was performed by 
comparison with GC-MS, based on proficiency testing 
samples specified by the RfB. Deviation from the GC-MS 
specified target concentrations of the proficiency testing 
serum cortisol samples were  ≤  10% (Table  4). CVs for 
the Cortisol II assay with the HM3/13A and HM3/13B 
GC-MS reference serum samples were – 4.5% and – 3.7%, 
respectively.
Method comparisons
For the method comparison studies, the serum samples 
covered a measuring range of 1.7–1735.0 nmol/L and the 
saliva samples from 1.5 to 209.5 nmol/L. The Passing-
Bablok regression analysis for the Cortisol II assay and the 
Cortisol assay (generation 1) with serum samples (n = 541) 
resulted in a slope of 0.76 [95% confidence intervals (CI), 
0.74–0.77] and an intercept of 10.3 nmol/L (95% CI, 6.09–
15.53) (Figure 1A). The correlation coefficient was 0.968. 
Bland-Altman analysis showed a combined mean bias of 
– 91.11 nmol/L (± 2 SD, – 238.91 to 56.69) across all sites 
(Figure 1B). For saliva samples (n = 404), the slope agree-
ment for Cortisol II vs. the Cortisol assay (generation 1) was 
1.21 (95% CI, 1.17–1.25) and the intercept was – 5.5 nmol/L 
(95% CI, – 5.97 to – 5.01), with a correlation coefficient of 
0.992 (Figure 1C). The Bland-Altman difference plots of the 
saliva samples on the Cortisol II vs. Cortisol (generation 1) 
assays revealed a mean bias of – 2.72 nmol/L (± 2 SD, – 9.94 
to 4.51; Figure 1D).
The Cortisol II assay was also compared with LC-MS/
MS, the current gold standard for cortisol measurement. 
For serum samples (n = 405), the agreement between 
the Cortisol II assay and LC-MS/MS was high, with a 
slope of 1.02 (95% CI, 1.00–1.04), an intercept of 4.473 
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nmol/L (95% CI, 0.94–9.45), and a correlation coefficient 
of 0.9863 (Figure 2A). The mean bias for serum samples 
measured on the Cortisol II assay compared with LC-MS/
MS was 14.55 nmol/L (± 2 SD, – 50.84 to 79.93; Figure 2B). 
The relationship between the Cortisol II assay vs. LC-MS/
MS for saliva samples (n = 253) was given with a slope of 
1.134 (95% CI, 1.10–1.16) and an intercept of 0.825 nmol/L 
(95% CI, 0.67–1.06) and a correlation coefficient of 0.9930 
(Figure 2C). For these comparisons, the mean bias was 
2.56 nmol/L (± 2 SD, – 5.54 to 10.65; Figure 2D).
Reference ranges
To calculate the references ranges, a total of 894 saliva and 
596 serum samples were collected from 300 self-reported 
healthy individuals and cortisol levels were measured using 
the Cortisol II assay (Table 5). Serum morning  cortisol con-
centrations (5th–95th percentile) were 166.1–507 nmol/L and 
afternoon concentrations were 73.8–291 nmol/L. Morning, 
afternoon, and midnight saliva cortisol concentrations (95th 
percentile) were 20.3, 6.94, and 7.56 nmol/L, respectively. For 
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Figure 1: Method comparison results and Bland-Altman plots of the Cortisol assay vs. the Cortisol II assay in serum or plasma samples 
(A) and (B), and saliva samples (C) and (D).
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midnight salivary cortisol, the median values were below 
the measuring range of the assay [LoD (3.0 nmol/L) and 
LoQ (1.5 nmol/L)] and the majority of individuals levels were 
below the LoD (81.6%) and the LoQ (61.5%). No statistically 
significant difference was observed between males and 
females for the serum or saliva samples.
Discussion
We here report the results of a performance evaluation 
study of a novel serum and salivary cortisol assay and, 
since serum and saliva cortisol measurements are key in 
the work-up of suspected adrenocortical diseases, these 
results are of clinical significance. The particular strength 
of this study was its multi-center and multi-lot design that 
aimed to simulate the long-term diagnostic application of 
this test in endocrine care. A main finding was that the 
between-laboratory and between-production lot repro-
ducibility was roughly 10% in the typical concentration 
range of salivary cortisol and roughly 6%–10% for serum 
cortisol. According to the concept of critical difference, 
this allows to distinguish a true cortisol concentration 
of a diagnostic sample of 11.3 nmol/L (upper limit of the 
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Figure 2: Method comparison results and Bland-Altman plots of the Cortisol II assay vs. LC-MS/MS in serum or plasma samples (A) and (B) 
and saliva samples (C) and (D).
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normal range observed in this study for midnight salivary 
cortisol) from 14.7 nmol/L with > 95% probability.
Despite being the gold standard, LC-MS/MS is still 
quite demanding and the complexity of the entire system 
makes routine measurement a very substantial challenge 
and it is still limited to very few laboratories [16–21]. An 
immunoassay offers a simpler approach in contrast. Com-
pared to the first generation Cortisol assay, we observed 
improved agreement of results with LC-MS/MS, which cur-
rently represents the gold standard for cortisol measure-
ment in the clinical laboratory. This improvement may be 
due to both the application of a more specific monoclonal 
antibody and the specification of calibrator concentra-
tions which were now based on a GC-MS reference method 
[28]. Close agreement with LC-MS/MS was observed for a 
large series of serum and saliva samples, as well as good 
recovery of the RfB proficiency testing samples, demon-
strated high accuracy of the study’s assay.
Daytime serum and saliva cortisol concentrations 
were studied in a large cohort of self-reported healthy 
adults to address the need for assay-specific cut-offs. The 
cut-offs varied depending on the time of day and whether 
serum or saliva was measured (Table 5). Of note, the major-
ity of the saliva midnight samples were below the LoQ (3.0 
nmol/L) and the LoD (1.5 nmol/L) of the assay compared 
to the morning and afternoon samples. However, the 
LoD and LoQ of the assay was not investigated as part of 
this study and was the manufacturer’s in-house data. It 
is important to state that the daytime data should not be 
used in a diagnostic approach in patients with suspected 
Cushing’s syndrome. These patients typically have normal 
serum cortisol concentration in the morning and the most 
important method to exclude Cushing’s syndrome is the 
dexamethasone suppression test. Alternatively, late-night 
cortisol secretion can be tested to exclude autonomous 
cortisol secretion in Cushing’s syndrome due to excess 
adrenocorticotropic hormone synthesis by hypophyseal 
adenoma or extra-hypophyseal tumors as a paraneo-
plastic syndrome or excess cortisol secretion by adrenal 
adenomas. In this respect, the midnight salivary cortisol 
concentrations observed with the Cortisol II assay in the 
299 healthy individuals are of substantial relevance in the 
context of this study. In this population, the 97.5th percen-
tile was 11.3 nmol/L. This is slightly higher than reported 
for the first generation Cortisol assay (8.9 nmol/L) [25]. 
However, it is still recommended that each laboratory 
should determine and apply their own assay specific cut-
offs in the diagnostic work-up of adrenocortical diseases 
when salivary cortisol is used since no conclusive system 
of between assay standardization of this emerging analyte 
in endocrine care has been achieved so far [46]. This is 
in contrast to serum cortisol measurement, which has a 
rather close between-assay agreement, as was observed in 
proficiency testing programs [47].
In summary, for the Cortisol II assay, we observed a 
degree of between-laboratory and between-production 
lot reproducibility and agreement with several assays of 
higher metrological order that we consider compatible 
with the diagnostic use of this assay. The Cortisol II assay 
will be beneficial to endocrinologists in assessing patients 
with adreno-cortisol disorders.
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Table 5: Cortisol II assay reference range values from serum or plasma and saliva of healthy individuals.
  n  Male/
female, n
  Median, 
nmol/L
  5th–95th percentile, 
nmol/L
  2.5th–97.5th percentile, 
nmol/L
  n (%) below 
LOQa
  n (%) 
below LODa
Serum or plasma a.m.   296  144/152  302.7   166.1–507.3   132.9–537.0  0  0
Serum or plasma p.m.   300  146/154  160.6   73.8–291.5   68.2–327.0  0  0
             
        95th percentile, nmol/L   97.5th percentile, nmol/L   
Saliva a.m.   297  144/153  8.0   20.3   24.1  24 (8.1)  5 (1.7)
Saliva p.m.   298  146/152  2.7   6.94   9.65  171 (57.4)  75 (25.2)
Saliva midnight   299  146/153  < MR   7.56   11.3  244 (81.6)  184 (61.5)
A.m., 06:00–10:00; p.m., 16:00–22:00; midnight, 00:00 ± 30 min; MR, measuring range; athe lower limit of the reference range is defined 
by the LoQ (3.0 nmol/L) and by the LoD (1.5 nmol/L).
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